DSpace Repository

Development of Favipiravir Secondary Standard from Favipiravir Tablets

Show simple item record

dc.contributor.author Intthira Thiangkrathok
dc.contributor.author Nattha Laobankho
dc.contributor.author Thunpitcha Pilasopa
dc.contributor.author Phurit Thanarangsarit
dc.contributor.author อินทิรา เที่ยงกระโทก
dc.contributor.author ณัฐฐา เหล่าบ้านค้อ
dc.contributor.author ธัญพิชชา พิลาโสภา
dc.contributor.author ภูริต ธนะรังสฤษฏ์
dc.contributor.other Huachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences. Student of Bachelor of Pharmaceutical Sciences en
dc.contributor.other Huachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences. Student of Bachelor of Pharmaceutical Sciences en
dc.contributor.other Huachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences. Student of Bachelor of Pharmaceutical Sciences en
dc.contributor.other Huachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences en
dc.date.accessioned 2024-12-04T11:53:47Z
dc.date.available 2024-12-04T11:53:47Z
dc.date.issued 2024
dc.identifier.uri https://has.hcu.ac.th/jspui/handle/123456789/3345
dc.description Proceedings of the 11th National and International Conference on "Research to Serve Society", 26 June 2024 at Huachiew Chalermprakiet University, Bangphli District, Samutprakarn, Thailand. p. 475-482. en
dc.description.abstract The aim of this study is to develop a secondary standard of favipiravir from favipiravir tablets for a replacement of costly reference standard. Firstly, favipiravir was isolated and purified from the powdered tablets by liquid-liquid extraction method using ethyl acetate and water. The total amount of extracted favipiravir yield 31.25% and the extract was consequently identified using Fourier-transform infrared (FT-IR) spectroscopy. Secondly, quantity or purity of extracted favipiravir was determined using a validated ultraviolet (UV)-visible spectrophotometric method. The analysis result showed that the purity of favipiravir was 95.98% (as is) which the acceptance criteria has been limited within 98.0-102.0%. Unfortunately, although the purity of developed favipiravir secondary standard was nearly met the criteria, it could be preliminary used as a standard substance in some routine pharmaceutical laboratory procedures, such as identification, in-process quality control, including pharmacological studies. en
dc.language.iso en_US en
dc.rights มหาวิทยาลัยหัวเฉียวเฉลิมพระเกียรติ en
dc.subject Secondary Standard en
dc.subject สารมาตรฐานทุติยภูมิ en
dc.subject Favipiravir en
dc.subject ฟาวิพิราเวียร์ en
dc.subject COVID-19 (Disease) en
dc.subject โควิด-19 (โรค) en
dc.subject COVID-19 Pandemic, 2020- en
dc.subject การระบาดใหญ่ของโควิด-19, ค.ศ. 2020- en
dc.subject UV-visible spectrophotometry en
dc.subject อัลตราไวโอเลต-วิสิเบิลเสปกโทรโฟโตมิเตอร์ en
dc.title Development of Favipiravir Secondary Standard from Favipiravir Tablets en
dc.type Proceeding Document en


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account